Showing results (271-280 of 295) with videos related to
Sort By:
Pageof 30
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)K Spieth, R Kaufmann, R Dummer, et al.Nature Aging|February 21, 2022
Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutationsSundus F Shalabi, Masaru Miyano, Rosalyn W Sayaman, et al.Frontiers in Cell and Developmental Biology|May 3, 2018
Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug ResistanceTiina A Jokela, Agnete S T Engelsen, Agata Rybicka, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognitionJ J Grob, A Guminski, J Malvehy, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomasJ J Grob, C Gaudy-Marqueste, A Guminski, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialT K Eigentler, R Gutzmer, A Hauschild, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre studyG A McArthur, M Maio, A Arance, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2011
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trialF Egberts, R Gutzmer, S Ugurel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyD Schadendorf, M M Amonkar, M Milhem, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.Pageof 30